Search for a Cure for Chronic Hepatitis B Infection: How Close Are We?

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 May 29

PMID 26019743

Citations 3

Authors

Wah Wah Phyo

Alex Yu Sen Soh

Seng Gee Lim

Guan Huei Lee

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B (CHB) remains a significant unmet medical need, with 240 million chronically infected persons worldwide. It can be controlled effectively with either nucleoside/nucleotide-based or interferon-based therapies. However, most patients receiving these therapies will relapse after treatment withdrawal. During recent years, the advances in molecular biology and immunology have enabled a better understanding of the viral-host interaction and inspired new treatment approaches to achieve either elimination of the virus from the liver or durable immune control of the infection. This review aims to provide a brief overview on the potential new therapies that may overcome the challenge of persistent CHB infection in the near future.

Citing Articles

Design and Synthesis of Hepatitis B Virus (HBV) Capsid Assembly Modulators and Evaluation of Their Activity in Mammalian Cell Model.

Spunde K, Vigante B, Dubova U, Sipola A, Timofejeva I, Zajakina A Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890072 PMC: 9317397. DOI: 10.3390/ph15070773.

Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates.

Zhang X, Wang J, Lu J, Li R, Zhao S Virol J. 2018; 15(1):111.

PMID: 30041659 PMC: 6056916. DOI: 10.1186/s12985-018-1026-3.

Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population.

Casillas R, Tabernero D, Gregori J, Belmonte I, Cortese M, Gonzalez C World J Gastroenterol. 2018; 24(6):680-692.

PMID: 29456407 PMC: 5807671. DOI: 10.3748/wjg.v24.i6.680.

References

Seeger C, Mason W . Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1):51-68. PMC: 98986. DOI: 10.1128/MMBR.64.1.51-68.2000. View

Cho M, Song J, Kim H, Park S, Jung G . Structure-based design and biochemical evaluation of sulfanilamide derivatives as hepatitis B virus capsid assembly inhibitors. J Enzyme Inhib Med Chem. 2012; 28(5):916-25. DOI: 10.3109/14756366.2012.694879. View

Xia Y, Lucifora J, Reisinger F, Heikenwalder M, Protzer U . Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA". Science. 2014; 344(6189):1237. DOI: 10.1126/science.1254083. View

Liaw Y . HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009; 3(3):425-33. PMC: 2748370. DOI: 10.1007/s12072-009-9140-3. View

Lai C, Ahn S, Lee K, Um S, Cho M, Yoon S . Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2013; 63(6):996-1004. DOI: 10.1136/gutjnl-2013-305138. View

Newbold J, Xin H, Tencza M, Sherman G, Dean J, Bowden S . The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995; 69(6):3350-7. PMC: 189047. DOI: 10.1128/JVI.69.6.3350-3357.1995. View

Chan H, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto M . Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011; 55(5):1121-31. DOI: 10.1016/j.jhep.2011.06.006. View

Lopatin U, Wolfgang G, Tumas D, Frey C, Ohmstede C, Hesselgesser J . Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther. 2013; 18(3):409-18. DOI: 10.3851/IMP2548. View

Jilbert A, Freiman J, Gowans E, Holmes M, Cossart Y, Burrell C . Duck hepatitis B virus DNA in liver, spleen, and pancreas: analysis by in situ and Southern blot hybridization. Virology. 1987; 158(2):330-8. DOI: 10.1016/0042-6822(87)90205-4. View

10.

Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M . Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009; 106(47):19975-9. PMC: 2775998. DOI: 10.1073/pnas.0908365106. View

11.

Uhl P, Fricker G, Haberkorn U, Mier W . Current status in the therapy of liver diseases. Int J Mol Sci. 2014; 15(5):7500-12. PMC: 4057686. DOI: 10.3390/ijms15057500. View

12.

Manjunath N, Yi G, Dang Y, Shankar P . Newer gene editing technologies toward HIV gene therapy. Viruses. 2013; 5(11):2748-66. PMC: 3856413. DOI: 10.3390/v5112748. View

13.

Wu T, Coates L, Aldrich C, Summers J, Mason W . In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 1990; 175(1):255-61. DOI: 10.1016/0042-6822(90)90206-7. View

14.

Jiang M, Broering R, Trippler M, Poggenpohl L, Fiedler M, Gerken G . Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat. 2014; 21(12):860-72. DOI: 10.1111/jvh.12216. View

15.

Schmitt S, Glebe D, Alving K, Tolle T, Linder M, Geyer H . Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. J Biol Chem. 1999; 274(17):11945-57. DOI: 10.1074/jbc.274.17.11945. View

16.

Campagna M, Liu F, Mao R, Mills C, Cai D, Guo F . Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol. 2013; 87(12):6931-42. PMC: 3676120. DOI: 10.1128/JVI.00582-13. View

17.

Schiffer J, Swan D, Stone D, Jerome K . Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol. 2013; 9(7):e1003131. PMC: 3701691. DOI: 10.1371/journal.pcbi.1003131. View

18.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X . Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176):1221-8. PMC: 6309542. DOI: 10.1126/science.1243462. View

19.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

20.

Hammond S, Caudy A, Hannon G . Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet. 2001; 2(2):110-9. DOI: 10.1038/35052556. View